Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab versus lenalidomide maintenance after transplant in newly diagnosed multiple myeloma
NL-OMON59885Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Aug 2022
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in multiple myeloma (MM) comparing Elranatamab with Lenalidomide (2 arms). Primary endpoint: Progression-free survival. Started Aug 2022; status: active, not recruiting.
02
Drugs
elranatamablenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON59885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59885.